Acadia Pharmaceuticals Confirms Delaware District Court Issued A Claim Construction Order In Favor Of Acadia Regarding Its '721 Formulation Patent For NUPLAZID®
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals Inc. received a favorable Claim Construction Order from the U.S. District Court for the District of Delaware regarding its '721 formulation patent for NUPLAZID®, a drug for Parkinson's Disease Psychosis. The Court ruled in favor of Acadia on all disputed claim construction points, affirming the strength of the patent. Consequently, the scheduled Markman hearing has been cancelled, with the trial set for December 2024.
December 14, 2023 | 7:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acadia Pharmaceuticals Inc. secured a legal win as the Delaware District Court ruled in favor of its '721 patent for NUPLAZID®, potentially strengthening its market position and exclusivity for the treatment.
The favorable court ruling on the '721 patent for NUPLAZID® is a significant legal victory for Acadia Pharmaceuticals, likely reinforcing its intellectual property rights and potentially deterring generic competition. This could lead to sustained revenue from NUPLAZID® and is seen as a positive development for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100